GKHT Medical Technology Co., Ltd. (SHE:301370)
China · Delayed Price · Currency is CNY 11.42
-0.08 (-0.70%)
At close: Feb 13, 2026
GKHT Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,177 | 7,303 | 7,446 | 6,327 | 5,814 | 4,798 |
Other Revenue | 43.34 | 43.34 | 36.81 | 32.6 | 32.9 | 64.48 |
| 7,220 | 7,346 | 7,483 | 6,360 | 5,847 | 4,862 | |
Revenue Growth (YoY) | 0.26% | -1.82% | 17.66% | 8.76% | 20.27% | 14.50% |
Cost of Revenue | 6,480 | 6,579 | 6,626 | 5,536 | 5,043 | 4,153 |
Gross Profit | 740.14 | 767.52 | 856.87 | 823.84 | 804.55 | 708.71 |
Selling, General & Admin | 537.04 | 514.73 | 513.18 | 442.53 | 386.44 | 335.96 |
Research & Development | 10.11 | 10.95 | 12.9 | 12.4 | 10.55 | 8.16 |
Other Operating Expenses | 21.31 | 21 | 19.25 | 19.47 | 19.2 | 7.15 |
Operating Expenses | 570.67 | 537.8 | 530.41 | 501.53 | 440.1 | 369.98 |
Operating Income | 169.47 | 229.72 | 326.46 | 322.32 | 364.45 | 338.73 |
Interest Expense | -38.74 | -60.95 | -88.18 | -119.32 | -128.96 | -119.14 |
Interest & Investment Income | 5.36 | 6.34 | 5.62 | 3.18 | 2.85 | 2.44 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | -0.1 | -0.28 | 0.18 | -0.74 |
Other Non Operating Income (Expenses) | -5.7 | -5.59 | -8.37 | -19.32 | -8.46 | -8.12 |
EBT Excluding Unusual Items | 130.32 | 169.45 | 235.43 | 186.58 | 230.07 | 213.17 |
Gain (Loss) on Sale of Investments | -2.39 | -0.52 | -4.99 | - | - | - |
Gain (Loss) on Sale of Assets | -0.33 | -0.21 | -0.18 | 0.22 | -0.03 | - |
Asset Writedown | -2.76 | -0.07 | -0.81 | -0.22 | 0.01 | -0 |
Legal Settlements | - | - | - | - | - | -2.92 |
Other Unusual Items | 30.63 | 20.22 | 6.63 | 9.23 | 11.78 | 6.13 |
Pretax Income | 155.47 | 188.86 | 236.08 | 195.81 | 241.84 | 216.38 |
Income Tax Expense | 30.66 | 37.13 | 65.37 | 53.71 | 62 | 58.22 |
Earnings From Continuing Operations | 124.82 | 151.74 | 170.71 | 142.1 | 179.84 | 158.16 |
Minority Interest in Earnings | -26.56 | -21.07 | -16.83 | -17.19 | -28.63 | -12.14 |
Net Income | 98.25 | 130.66 | 153.88 | 124.91 | 151.21 | 146.02 |
Net Income to Common | 98.25 | 130.66 | 153.88 | 124.91 | 151.21 | 146.02 |
Net Income Growth | -39.59% | -15.09% | 23.19% | -17.39% | 3.55% | -2.27% |
Shares Outstanding (Basic) | 471 | 467 | 427 | 403 | 398 | 395 |
Shares Outstanding (Diluted) | 471 | 467 | 427 | 403 | 398 | 395 |
Shares Change (YoY) | -0.49% | 9.17% | 6.08% | 1.26% | 0.83% | 8.29% |
EPS (Basic) | 0.21 | 0.28 | 0.36 | 0.31 | 0.38 | 0.37 |
EPS (Diluted) | 0.21 | 0.28 | 0.36 | 0.31 | 0.38 | 0.37 |
EPS Growth | -39.29% | -22.22% | 16.13% | -18.42% | 2.70% | -9.76% |
Free Cash Flow | 404.58 | 606.32 | 562.37 | 214.1 | 145.78 | -291.29 |
Free Cash Flow Per Share | 0.86 | 1.30 | 1.32 | 0.53 | 0.37 | -0.74 |
Dividend Per Share | 0.084 | 0.084 | 0.118 | - | - | - |
Dividend Growth | -28.81% | -28.81% | - | - | - | - |
Gross Margin | 10.25% | 10.45% | 11.45% | 12.95% | 13.76% | 14.58% |
Operating Margin | 2.35% | 3.13% | 4.36% | 5.07% | 6.23% | 6.97% |
Profit Margin | 1.36% | 1.78% | 2.06% | 1.96% | 2.59% | 3.00% |
Free Cash Flow Margin | 5.60% | 8.25% | 7.51% | 3.37% | 2.49% | -5.99% |
EBITDA | 209.56 | 270.7 | 368.63 | 363.89 | 391.73 | 351.66 |
EBITDA Margin | 2.90% | 3.69% | 4.93% | 5.72% | 6.70% | 7.23% |
D&A For EBITDA | 40.09 | 40.98 | 42.17 | 41.57 | 27.28 | 12.93 |
EBIT | 169.47 | 229.72 | 326.46 | 322.32 | 364.45 | 338.73 |
EBIT Margin | 2.35% | 3.13% | 4.36% | 5.07% | 6.23% | 6.97% |
Effective Tax Rate | 19.72% | 19.66% | 27.69% | 27.43% | 25.64% | 26.91% |
Revenue as Reported | 7,220 | 7,346 | 7,483 | 6,360 | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.